Insurance Bureau issued the "Announcement on the Results of the Negotiations for the Su Yansu Xutonghuai Public Medical Institutions' Medical Consumables Alliance to Bring Volume Renewal and Expansion", showing:>
Ao Hushan: Call on all people to learn cardiopulmonary resuscitation techniques and set up "National First Aid Day"
Time of Update: 2021-03-25
According to Ao Hushan, taking Shenzhen as an example, a total of 5,000 AEDs have been deployed in the past three years, and 23 patients have been successfully rescued, benefiting 23 families.
Pioneering pharmaceutical proclosamine treatment of severe new crown patients clinical trial death risk reduced by 92%
Time of Update: 2021-03-22
Hospital stay shortened by 9 days544px;white-space:normal;background-color:#FFFFFF;box-sizing:border-box !important;'> 544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box !important;overflow-wrap:break-word !important;'> Prokalamide treatment group (N=294) Placebo control group (N=296) Number of people percentage Number of people percentage mortality rate 11 3.
AACR 2021: Anti-CD47 antibody AO-176 treats solid tumors and multiple myeloma, with positive results in preclinical trials
Time of Update: 2021-03-19
In addition to blocking the external signal, AO-176 also have other mechanisms, including direct tumor cell killing induced and DAMPs (damage associated molecular patterns), leading to immune immunogenic cell death.
FSHW: Beneficial effects of AOS-iron supplements on the gut structure and microbiome of IDA rats
Time of Update: 2021-03-17
and mood. Some diseases are often accompanied by changes in the intestinal microbiota. Adjusting the intestinal microbiota can be considered an effective way to alleviate the disease
Health and Wellness Commission: 30 new crown confirmed 92 cases of local 73 cases
Time of Update: 2021-02-02
(Shanghai 7 cases, Liaoning 3 cases, Guangdong 3 cases, Fujian 2 cases, Shaanxi 2 cases, Jiangsu 1 case, Sichuan 1 case), 73 local cases (63 cases in Jilin, 9 cases in Heilongjiang, 1 case in Hebei); 135 new cases were cured and discharged from
Due to process conditions, the potentially heavy drug Ao nitrogen flat compound was delayed by the FDA approval
Time of Update: 2021-01-19
On Tuesday, NASDAQ-listed Company Alkermes announced that it had received a letter from the U.S. Food and Drug Administration (FDA) on its new drug, APKS 3831 (Ao nitrogenpine/samidorphan), for adults with schizophrenia and bisomethic type I disorders.
CD19 CAR-T Cell Therapy! Gilead Yescarta Treatment Recurrence/Difficult Inert Non-Hodgkin's Lymphoma (iNHL): Total remission rate of 92%!
Time of Update: 2020-12-18
data released at the ASH Annual Meeting showed that after receiving Yescarta's single infusion treatment, the medium follow-up was 17.5 months: 92% of the 104 patients with assessable efficacy were in remission (ORR-92%) and 76% were fully relieved (CR-76%).
in Meshadon: complete 2 years of Keytruda treatment of patients with a 3-year survival rate of 92%!
Time of Update: 2020-11-02
compared to pure chemotherapy (n-63): (1) objective remission rate (ORR:58% vs 33%) was significantly increased, and medium remission duration (DOR) was extended by more than one year (36) .3 months) vs 22.8 months) ;(2) No progression lifetime
Total mitigation rate of 92%! FDA grants Gilead CD47 single anti-magrolimab breakthrough drug: Treatment of bone marrow growth syndrome!
Time of Update: 2020-10-07
September 16, 2020 // -- Gilead Sciences recently announced that the U.S. Food and Drug Administration (FDA) has granted magolimab Breakthrough Drug Qualification (BTD), the first anti-CD47 monoclonal antibody to treat newly diagnosed myeloid growth syndrome (MDS).
Junshi Bio announced its interim results for 2020, with research and development investment up 92% year-on-year!
Time of Update: 2020-09-28
press release, the company has made significant progress in product commercialization, clinical trials and pipeline expansion, with unaudited revenue of $575 million, up 86% year-on-year.
for New Allergies: Hematological Remission Rate Up to 92%
Time of Update: 2020-09-26
September 11, 2020 // -- Johnson and Johnson (JNJ)'s Janssen Pharmaceuticals recently announced that it has filed a Supplemental Biologics Licensing Application (SBLA) with the U.S. Food and Drug Administration (FDA) seeking approval for Darzalex
Wen's, Saint-Agriculture, Ao Nong these three agricultural and animal husbandry enterprises 2020 half-year results, revealed what.
Time of Update: 2020-09-05
With listed companies have announced the first half of 2020 earnings report, some people are happy and worried! What about the recent release of three earnings reports from Wen, Aon and Saint-Agriculture, representing three companies in the pig
Methyl esterification: New nickel modification seislicing can be efficient lysing with NAD-synthetic path mutants (ao-1 and qs-1)
Time of Update: 2020-08-08
differs from the two-step remediation synthesis of NAD in mammals, which is the four-step Preiss-Handler pathway in terrestrial plants, and where there are a variety of derivatives of nicotine (nicotine, NA) specifically present in plants (glycosylation, methylation, etc.).
hydroxybutyrate magnesium potassium), reducing sodium intake by 92%!
Time of Update: 2020-07-28
The U.S. Food and Drug Administration () has approved an oral solution (sodium hydroxybutylate, potassium, magnesium, calcium) for the treatment of denarcing or excessive daytime drowsiness in patients with narcolepsy (narcolepsy) and older
Death toll from bird flu in Indonesia rises to 92
Time of Update: 2020-07-06
Indonesia is currently one of the worst countries to have an avian influenza outbreak, with more than 110 people infected with the highly pathogenic avian influenza virus, of whom 92 have died.
Johnson and Johnson Darzalex combination of first-line treatment AL Phase III Clinical: Hematology remission rate as high as 92%
Time of Update: 2020-06-26
Original source: Subcutane Daratumab Combination Results in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in The Treatment of Patients with Diagnosed Light Chain (AL) Amyloidosis the original title: Light Chain (AL
Interpretation of exclusive medical insurance bureau: 92% of consumables are eliminated
Time of Update: 2020-06-19
in this regard, sabilan instruments visited the relevant person in charge of the bidding and Purchasing Department of Liaoyang medical insurance bureau to learn about the negotiation and quotation in this centralized purchase.